Pass the FDA Modernization Act 3.0.

Ken Calvert · California · Republican

policy impact 3.00 specificity 1.00 extraction confidence 91%

Contest this claim

Occurrences

Evidence

FDA said it would begin reducing animal-testing requirements for monoclonal antibodies and other drugs, starting immediately for IND applications and using AI, cell lines, organoids, and other NAMs.

Official FDA policy move toward non-animal testing, but it is administrative action rather than passage of an FDA Modernization Act 3.0.

unresolved later_term

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs | FDA
primary · model gpt-5.4-mini · confidence 86%

Contest this evidence item

The roadmap says FDA will reduce animal testing in preclinical safety studies with validated NAMs and cites Congress's 2022 FDA Modernization Act 2.0 as the recent legislative baseline.

The agency's roadmap shows policy progress, but it references the prior 2.0 law and does not evidence passage of a 3.0 act.

unresolved later_term

download
primary · model gpt-5.4-mini · confidence 90%

Contest this evidence item

Assessments

unresolved unknown

The promise is specifically to pass the FDA Modernization Act 3.0. The evidence shows later FDA administrative progress in reducing animal-testing requirements, but those actions explicitly build on the 2022 FDA Modernization Act 2.0 and do not show that a 3.0 act was enacted. There is also no evidence here that Ken Calvert sponsored, wrote, or materially advanced a 3.0 measure to final passage. Because the candidate remains in federal office and the record provided does not establish either enactment or a definitive failed end-state, the best judgment is unresolved rather than delivered or partial.

provider codex_cli · model gpt-5.4 · confidence 88%